This study examined the efficacy of gene therapy of lung adenocarcinoma using 
specifically controlled type I herpes simplex virus recombinant vector 
expressing Gibbon ape leukemia virus membrane fusion glycoprotein gene 
(GALV.fus). Recombinant HSV-I plasmid carrying target transgene was constructed, 
and recombinant viral vector was generated in Vero cells using Lipofectamine 
transfection. Viral vector was introduced into lung adenocarcinoma A549 cells or 
human fetal fibroblast HFL-I GNHu 5 cells, or inoculated into human lung 
adenocarcinoma xenografts in nude mice. The anti-tumor and cytotoxic effects of 
GALV-FMG, the transgene, were examined in these cell and animal models. 
Expression of GALV-FMG in xenographs achieved 100 % tumorigenicity. Recombinant 
HSV-I viral vector also exhibited significant tumor cell killing effect in 
vitro. Relative survival rates of tumor cells treated with GALV-FMG or control 
vectors were, respectively, 20 and 70 %. GALV.fus has a potent anti-tumor effect 
against lung cancer both in vitro and in vivo. This anti-tumor potential 
provides foundation for further studies with this vector.